Case presentation

A 35-old year healthy Caucasian football player man presented with a 3years history of anterior knee pain and tenderness in his right patellar tendon insertion. He referred a constant dull aching pain with walking, forcing to discontinue sport because of the severity of his pain. He has been previously treated with conservative therapy and with platelet-rich plasma (PRP) injections; however his pain did not improve. At presentation, pain was rated as 7 out of 10 on Visual Analogue Scale (VAS). Color Doppler ultrasound examination revealed signs of tendinosis with significant neovascularization, formed by immature tortuous and dilated vessels into intratendinous mass (Figure 1A). Furthermore, color Doppler scans showed areas of intratendinous edema in the proximal patellar-tendon interface (Figure 1A). After discussing the various treatment options, the patient opted to try etamsylate injection and signed an informed consent. Lidocaine was infiltrated into the skin overlying the right patellar tendon. 4ml etamsylate (Dicynone®, Sanofi-Aventis. France) were injected under ultrasound guidance into peritendinous patellar tendon tissue. The procedure was uneventful. At 2weeks follow-up visit, patient reported a marked improvement of his pain (VAS was rated as 2), and color Doppler ultrasound scans showed a significant reduction of neovessels and disappearance of tendinous edema (Figure 1B). Furthermore, at 4weeks tendon hypervascularity decreased (Figure 1C) and pain strongly ameliorated (VAS=1). Patient could return to his previous level of sport without any restrictions.

Figure 1 The presence of neovessels is detected in the patellar tendon using color Doppler ultrasound. Longitudinal scans taken before (A) and after two (B) and four weeks(C) of etamsylate injection. Diminution of hypervascularity is demonstrated after injection of etamsylate. Note the reduction of edema (*) after two weeks of treatment.
Discussion

Patellar tendinosis is a common painful difficult-to-treat overuse injury of the patellar tendon with a negative impact on the carriers of many athletes. The overall prevalence of patellar tendinopathy yields to 14% in elite athletes and increases up to 45% in high-risk sports such as basketball and volleyball. There are a wide variety of treatment options available, the majority of which are non-operative. No consensus exists on the optimal method of treatment. Anti-inflammatory agents and injectable agents have shown mixed results. In approximately 10% of conservatively treated patients, conservative treatment fails and surgery is required. Since tendinopathy appears to be a highly active process of ongoing neovascularization, anti-angiogenic therapies could be a new approach for treating tendinopathies. It has been reported that nerves appear to travel in close association to tendon neovessels. This finding suggests that angiogenesis plays an important role in pain-experienced in tendinopathy condition. These data are in accordance with clinical studies showing that strategies to destroy neovessels (i.e local injection of a sclerosing agent, polidocanol) lead to pain improvement. Etamsylate, an inhibitor of fibroblast growth factor (FGF), when locally applied, suppresses FGF-driven angiogenesis. Since FGF participates in nociception, injecting etamsylate into the areas of tendinopathy resulted in clinical improvement.

Learning points

i. Neovascularization has been demonstrated in painful tendon from sport activity.

ii. Hypervascularity is one of the causes of tendon pain due to parallel migration of neovascular innervation.

iii. Etamsylate injection in pathologic patellar tendon resulted in clinical improvement.

iv. Etamsylate, acting as an FGF inhibitor, could destroy pathologic tendon neovessels and decrease the nociceptive FGF-related activities.

Acknowledgements

None.

Conflict of interest

The author declares no conflict of interest.

References